Gain Therapeutics, Inc. Common Stock (GANX) is a publicly traded Healthcare sector company. As of May 21, 2026, GANX trades at $1.65 with a market cap of $69.10M and a P/E ratio of -2.70. GANX moved +4.09% today. Year to date, GANX is -44.44%; over the trailing twelve months it is -13.61%. Its 52-week range spans $1.41 to $4.34. Analyst consensus is strong buy with an average price target of $7.20. Rallies surfaces GANX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Gain Therapeutics, Inc. Common Stock (GANX) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. GANX moved +4.09% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $1.65 |
| Market Cap | $69.10M |
| P/E Ratio | -2.70 |
| EPS | $-0.61 |
| Dividend Yield | 0.00% |
| 52-Week High | $4.34 |
| 52-Week Low | $1.41 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-20.16M |
| Gross Margin | 0.00% |
5 analysts cover GANX: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $7.20.